This is a competing continuation for a grant entitled """"""""Biomarkers of Cognitive Decline among Normal Individuals: The BIOCARD Cohort'(see FOA: PAR-13-148). The BIOCARD study is a longitudinal, observational study of 349 individuals who were cognitively normal and primarily middle aged (mean age=57.1) at enrollment. By design, more than two-thirds had a family history of Alzheimer's disease (AD). The primary goal was to follow individuals from normal cognition to mild cognitive impairment (MCI) or dementia, so that it would be possible to identify biomarkers that predicted progression. The rationale for this study design is that several lines of evidence indicate that AD pathophysiological processes begin to develop many years, if not decades, before AD dementia is diagnosed. This long prodromal phase provides a 'window of opportunity'during which symptoms are minimal (if present at all) but therapeutic intervention may have the greatest opportunity of success. The BIOCARD study is in a unique position to examine 'preclinical AD', since the participants: (1) have been followed for up to 18 years (mean follow-up = 12.1 yrs), (2) are entering a period of accelerating risk, and (3) 63 of those alive have developed mild cognitive impairment (MCI) or dementia. Our overall objectives are to further advance the study of preclinical AD by: (1) clarifying the pattern and rate of changes in AD biomarkers (including CSF, MRI, amyloid imaging and blood) and cognition that occur, as well as evaluate potential new biomarkers, (2) maximizing our data by working collaboratively with several research groups who have comparable data, and (3) providing a publicly accessible database, to include biological specimens, for researchers in the field. The long duration of follow-up for the cohort is based on the fact that the study was established in 1995 by investigators in the intramural program of the NIH. The study was stopped for administrative purposes in 2005. Our investigative team was funded in July 2009 to re-enroll the participants and re-initiate longitudinal data collection. Wit this application, we are requesting funds to continue the longitudinal clinical and cognitive assessment of the cohort, collect more CSF, more MRI scans, and to initiate acquisition of positron emission tomography (PET), using [11-C] PiB, in the participants who remain cognitively normal (n=201). Though a number of studies around the world have begun to examine cognitively normal individuals with similar goals in mind, no study, to our knowledge, has up to 18 years of accumulated longitudinal data on changes in cognitive, CSF, and MRI measures first obtained when the subjects were cognitively normal and the majority were middle aged.
The overarching goal of the research is to improve our understanding of the earliest stages at which Alzheimer's disease develops. Interventions may have the greatest opportunity of success if it is possible to identify people in the earliest phase of disease and treat them. The major goal of the study is to identify factors that predict cognitiv decline among normal individuals who were in middle age when first evaluated.
|Sathe, Gajanan; Na, Chan Hyun; Renuse, Santosh et al. (2018) Phosphotyrosine profiling of human cerebrospinal fluid. Clin Proteomics 15:29|
|Hinkle, Jared T; Perepezko, Kate; Bakker, Catherine C et al. (2018) Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. Int J Geriatr Psychiatry 33:e131-e139|
|Chan, Carol K; Soldan, Anja; Pettigrew, Corinne et al. (2018) Depressive symptoms in relation to clinical symptom onset of mild cognitive impairment. Int Psychogeriatr :1-9|
|Albert, Marilyn; Zhu, Yuxin; Moghekar, Abhay et al. (2018) Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. Brain :|
|Blauwendraat, Cornelis; Pletnikova, Olga; Geiger, Joshua T et al. (2018) Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiol Aging :|
|Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872|
|Hohman, Timothy J; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol 75:989-998|
|Soldan, Anja; Pettigrew, Corinne; Albert, Marilyn (2018) Evaluating Cognitive Reserve Through the Prism of Preclinical Alzheimer Disease. Psychiatr Clin North Am 41:65-77|
|Chiang, Angie C A; Fowler, Stephanie W; Reddy, Rohit et al. (2018) Discrete Pools of Oligomeric Amyloid-? Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. Am J Pathol 188:739-756|
|Gross, Alden L; Hassenstab, Jason J; Johnson, Sterling C et al. (2017) A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. Alzheimers Dement (Amst) 8:147-155|
Showing the most recent 10 out of 52 publications